Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Working Capital Changes (2016 - 2025)

Ani Pharmaceuticals' Other Working Capital Changes history spans 16 years, with the latest figure at $4.5 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 163.44% year-over-year to $4.5 million; the TTM value through Dec 2025 reached $5.0 million, up 335.98%, while the annual FY2025 figure was $5.0 million, 335.98% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was $4.5 million at Ani Pharmaceuticals, down from $6.5 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $8.4 million in Q4 2023 and bottomed at -$9.8 million in Q2 2025.
  • The 5-year median for Other Working Capital Changes is -$77500.0 (2021), against an average of $629050.0.
  • The largest YoY upside for Other Working Capital Changes was 415.6% in 2025 against a maximum downside of 2219.58% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at $1.3 million in 2021, then surged by 163.91% to $3.4 million in 2022, then soared by 145.36% to $8.4 million in 2023, then plummeted by 79.79% to $1.7 million in 2024, then skyrocketed by 163.44% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Other Working Capital Changes are $4.5 million (Q4 2025), $6.5 million (Q3 2025), and -$9.8 million (Q2 2025).